These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 30548543)

  • 1. Identification of risk in cutaneous melanoma patients: Prognostic and predictive markers.
    Hyams DM; Cook RW; Buzaid AC
    J Surg Oncol; 2019 Jan; 119(2):175-186. PubMed ID: 30548543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New prognostic factors of cutaneous melanoma: a review of the literature.
    Li N; Mangini J; Bhawan J
    J Cutan Pathol; 2002 Jul; 29(6):324-40. PubMed ID: 12135463
    [No Abstract]   [Full Text] [Related]  

  • 3. Emerging Biomarkers in Cutaneous Melanoma.
    Eisenstein A; Gonzalez EC; Raghunathan R; Xu X; Wu M; McLean EO; McGee J; Ryu B; Alani RM
    Mol Diagn Ther; 2018 Apr; 22(2):203-218. PubMed ID: 29411301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Association of
    Wang X; Yu X; Krauthammer M; Hugo W; Duan C; Kanetsky PA; Teer JK; Thompson ZJ; Kalos D; Tsai KY; Smalley KSM; Sondak VK; Chen YA; Conejo-Garcia JR
    Cancer Epidemiol Biomarkers Prev; 2020 Sep; 29(9):1792-1799. PubMed ID: 32611582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor biomarkers in melanoma.
    Ugurel S; Utikal J; Becker JC
    Cancer Control; 2009 Jul; 16(3):219-24. PubMed ID: 19556961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-omics analysis reveals inflammatory biomarkers for skin melanoma prognosis.
    Zhan ZQ; Li JX; Hu XL
    Pigment Cell Melanoma Res; 2024 Jul; 37(4):510-513. PubMed ID: 38679454
    [No Abstract]   [Full Text] [Related]  

  • 7. Chemokines in the melanoma metastasis biomarkers portrait.
    Neagu M; Constantin C; Longo C
    J Immunoassay Immunochem; 2015; 36(6):559-66. PubMed ID: 25839711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Validation of Tumor Immunogenicity Based Gene Signature for Skin Cancer Risk Stratification.
    Yavartanoo M; Yi GS
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLT8D1 overexpression as a novel prognostic biomarker in human cutaneous melanoma.
    Hu H; Li Z; Zhou Y; Zhang Y; Zhao L; Zhao W; Huang Y; Song X
    Melanoma Res; 2019 Dec; 29(6):612-620. PubMed ID: 31305325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of diagnostic and prognostic markers in melanoma.
    Levine D; Fisher DE
    Methods Mol Biol; 2014; 1102():177-97. PubMed ID: 24258980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Leukocyte Infiltration Score Defined by a Gene Signature Predicts Melanoma Patient Prognosis.
    Zhao Y; Schaafsma E; Gorlov IP; Hernando E; Thomas NE; Shen R; Turk MJ; Berwick M; Amos CI; Cheng C
    Mol Cancer Res; 2019 Jan; 17(1):109-119. PubMed ID: 30171176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting the clinical outcome of melanoma using an immune-related gene pairs signature.
    Meng L; He X; Zhang X; Zhang X; Wei Y; Wu B; Li W; Li J; Xiao Y
    PLoS One; 2020; 15(10):e0240331. PubMed ID: 33031392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stage-specific prognostic biomarkers in melanoma.
    Cheng Y; Lu J; Chen G; Ardekani GS; Rotte A; Martinka M; Xu X; McElwee KJ; Zhang G; Zhou Y
    Oncotarget; 2015 Feb; 6(6):4180-9. PubMed ID: 25784655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline determinants of clinical outcome of cutaneous melanoma.
    Vogelsang M; Wilson M; Kirchhoff T
    Pigment Cell Melanoma Res; 2016 Jan; 29(1):15-26. PubMed ID: 26342156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma long non-coding RNA signature predicts prognostic survival and directs clinical risk-specific treatments.
    Chen X; Guo W; Xu XJ; Su F; Wang Y; Zhang Y; Wang Q; Zhu L
    J Dermatol Sci; 2017 Mar; 85(3):226-234. PubMed ID: 27955882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of tumor suppressors KAI1 and p27 identifies a unique subgroup of primary melanoma patients with poor prognosis.
    Zhang G; Cheng Y; Chen G; Tang Y; Ardekani G; Rotte A; Martinka M; McElwee K; Xu X; Wang Q; Zhou Y
    Oncotarget; 2015 Sep; 6(26):23026-35. PubMed ID: 26246476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of miR-203 is decreased and associated with the prognosis of melanoma patients.
    Wang K; Zhang ZW
    Int J Clin Exp Pathol; 2015; 8(10):13249-54. PubMed ID: 26722525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular and pathomorphological prognostic markers for melanoma: Current approaches and prospects].
    Ruksha TG; Aksenenko MB; Shvetsova YI
    Arkh Patol; 2015; 77(4):71-77. PubMed ID: 26485783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of p62 expression in cutaneous malignant melanoma.
    Ellis RA; Horswell S; Ness T; Lumsdon J; Tooze SA; Kirkham N; Armstrong JL; Lovat PE
    J Invest Dermatol; 2014 May; 134(5):1476-1478. PubMed ID: 24270664
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical Implications of High-mobility Group Box-1 (HMGB1) and the Receptor for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A Systematic Review.
    Nguyen AH; Detty SQ; Agrawal DK
    Anticancer Res; 2017 Jan; 37(1):1-7. PubMed ID: 28011467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.